@article{f0a7bc405e5b4e8fa39d2f8328e48c9f,
title = "Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement",
abstract = "This paper reflects the position of the CKD-MBD workgroup, an official working group of ERA-EDTA and of the ERBP advisory board, the official guideline-producing body of ERA-EDTA, on the topic of the use of calcimimetics in patients with CKD stage 5D, as based on two recent meta-analysis",
author = "David Goldsmith and Adrian Covic and Marc Vervloet and Mario Cozzolino and Ionut Nistor and {AUTHOR GROUP} and Mark Vervloet and Vincent Brandenburg and Jordi Bover and Pieter Evenepoel and Ziad Massy and Sandro Mazzaferro and Pablo Urena-Torres and D. Abramowicz and D. Bolignano and {Cannata Andia}, G. and P. Cochat and A. Covic and L. Delvecchio and C. Drechsler and Eckardt, {K. U.} and D. Fouque and J. Fox and M. Haller and O. Heimburger and Jager, {K. J.} and E. Lindley and {Marti Monros}, {A. M.} and E. Nagler and R. Oberbauer and G. Spasovski and J. Tattersall and {van Biesen}, W. and {Vander Veer}, S. and R. Vanholder and C. Wanner and D. Wheeler and W. Whithers and A. Wiecek and C. Zoccali",
year = "2015",
doi = "https://doi.org/10.1093/ndt/gfv050",
language = "English",
volume = "30",
pages = "698--700",
journal = "Nephrology, dialysis, transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "5",
}